Alcon On Track To Submit Anecortave NDA By Year-End Despite Study Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Anecortave, in development for wet age-related macular degeneration, failed to reach its primary non-inferiority endpoint in a comparative study with Novartis/QLT’s Visudyne. Alcon is studying a device to control drug reflux that it believes may improve patient outcomes.